Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on October 24, 2017. The filing reports corporate governance changes effective as of October 24, 2017, specifically regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to eight members.
- New Appointments: Mr. Thomas Loewald and Ms. Katherine A. Eade were appointed as additional Class II independent directors.
- Term: The new directors will serve until the 2020 annual meeting of stockholders or until their successors are elected.
Compensation and Outlook
In connection with their appointments, Mr. Loewald and Ms. Eade are scheduled to receive non-qualified stock options on October 30, 2017. The grant size will be the greater of:
- Options with an aggregate Black-Scholes cash value of $120,000 (rounded to the nearest 100 shares).
- Options to acquire 25,000 shares.
The options have a ten-year term with an exercise price equal to the closing stock price on October 30, 2017. Vesting occurs in three equal installments on October 30, 2018, 2019, and 2020. The filing contains no forward-looking guidance, risk factors, or management commentary regarding financial performance.
Investor Verification Checklist
- Verify the closing stock price on October 30, 2017, to determine the exact exercise price and share count of the new options.
- Review the attached press release (Exhibit 99.1) for additional biographical details on the new directors.
- Confirm the impact of the new option grants on the company's total share count and potential dilution in future filings.